In Chronic Spontaneous Urticaria, Complete Response to Antihistamine Treatment Is Linked to Low Disease Activity.

Abstract

INTRODUCTION:

The use of predictors of response to a specific treatment in patients with chronic spontaneous urticaria (CSU) can improve disease management, help prevent unnecessary healthcare costs, and save time. In this study, we aimed to identify predictors of complete response to standard-dosed and higher than standard-dosed antihistamine treatments in patients with CSU.

METHODS:

Medical records of 475 CSU patients, 120 of them <18 years old, from 3 different centers were analyzed. We used 15 machine learning (ML) models as well as traditional statistical methods to predict complete response to standard-dosed and higher than standard-dosed antihistamine treatment based on 17 clinical parameters.

RESULTS:

CSU disease activity, which was assessed by urticaria activity score (UAS), was the only clinical parameter that predicted complete response to standard-dosed and higher than standard-dosed antihistamine treatment, with ML models and traditional statistics, for all age groups. Based on ROC analyses, optimal cut-off values of disease activity to predict complete response were UAS <3 and UAS <4 for standard-dosed (area under the ROC curve [AUC] = 0.69; p = 0.001) and higher than standard-dosed (AUC = 0.79; p = 0.001) antihistamine treatments, respectively. Also, ML models identified lower total IgE (<150 IU/mL) as a predictor of complete response to a standard-dosed antihistamine and lower CRP (<3.4 mg/mL) as a predictor of complete response to higher than standard-dose antihistamine treatment.

DISCUSSION:

In this study, we showed that patients with UAS <3 are highly likely to have complete response to standard-dosed AH and those with a UAS <4 are highly likely to have complete response to higher than standard-dosed AH treatment. Low CSU disease activity is the only universal predictor of complete response to AH treatment with both ML models and traditional statistics for all age groups.

• Authors: Murat Türk, Ragıp Ertaş, Ümit Murat Şahiner, Pavel Kolkhir, Bülent Enis Şekerel, Özge Soyer, Atıl Avcı, Mustafa Atasoy, Kemal Özyurt, Yekta Türk, Engin Zeydan, Marcus Maurer
• Journal: International archives of allergy and immunology (Int Arch Allergy Immunol) Vol. 184 Issue 5 Pg. 421-432 ( 2023) ISSN: 1423-0097 [Electronic] Switzerland
• PMID: 36652936 (Publication Type: Journal Article)
• Copyright: © 2023 S. Karger AG, Basel.

Chemical References

• Histamine Antagonists
• Histamine H1 Antagonists
• Omalizumab

Topics

• Humans
• Adolescent
• Chronic Disease
• Chronic Urticaria (drug therapy)
• Histamine Antagonists (therapeutic use)
• Histamine H1 Antagonists (adverse effects)
• Urticaria (drug therapy)
• Omalizumab (therapeutic use)